HRP20000366B1 - Long acting injectable formulations containing hydrogenated castor oil - Google Patents

Long acting injectable formulations containing hydrogenated castor oil

Info

Publication number
HRP20000366B1
HRP20000366B1 HR20000366A HRP20000366A HRP20000366B1 HR P20000366 B1 HRP20000366 B1 HR P20000366B1 HR 20000366 A HR20000366 A HR 20000366A HR P20000366 A HRP20000366 A HR P20000366A HR P20000366 B1 HRP20000366 B1 HR P20000366B1
Authority
HR
Croatia
Prior art keywords
hydrogenated castor
castor oil
long acting
formulations containing
injectable formulations
Prior art date
Application number
HR20000366A
Other languages
English (en)
Croatian (hr)
Inventor
James Williams B.
Rey Chern T.
Original Assignee
Merck & Co. Inc.
Merial Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26313620&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20000366(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9809792.6A external-priority patent/GB9809792D0/en
Application filed by Merck & Co. Inc., Merial Llc filed Critical Merck & Co. Inc.
Publication of HRP20000366A2 publication Critical patent/HRP20000366A2/hr
Publication of HRP20000366B1 publication Critical patent/HRP20000366B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HR20000366A 1997-12-03 2000-06-02 Long acting injectable formulations containing hydrogenated castor oil HRP20000366B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6737497P 1997-12-03 1997-12-03
GBGB9809792.6A GB9809792D0 (en) 1998-05-07 1998-05-07 Long acting injectable formulations containing hydrogenated castor oil
PCT/US1998/019016 WO1999027906A1 (en) 1997-12-03 1998-09-14 Long acting injectable formulations containing hydrogenated castor oil

Publications (2)

Publication Number Publication Date
HRP20000366A2 HRP20000366A2 (en) 2001-06-30
HRP20000366B1 true HRP20000366B1 (en) 2009-08-31

Family

ID=26313620

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20000366A HRP20000366B1 (en) 1997-12-03 2000-06-02 Long acting injectable formulations containing hydrogenated castor oil

Country Status (28)

Country Link
EP (1) EP1035835B1 (xx)
JP (1) JP3925900B2 (xx)
KR (1) KR100499438B1 (xx)
CN (1) CN1205921C (xx)
AR (1) AR017779A1 (xx)
AT (1) ATE249206T1 (xx)
AU (1) AU749006B2 (xx)
BG (1) BG65147B1 (xx)
BR (1) BR9815352A (xx)
CA (1) CA2312898C (xx)
CO (1) CO4970836A1 (xx)
DE (1) DE69818093T2 (xx)
DK (1) DK1035835T3 (xx)
EA (1) EA002497B1 (xx)
ES (1) ES2205550T3 (xx)
HK (1) HK1032917A1 (xx)
HR (1) HRP20000366B1 (xx)
HU (1) HU228617B1 (xx)
IL (1) IL136313A (xx)
ME (1) ME00855B (xx)
NO (1) NO329469B1 (xx)
NZ (1) NZ504783A (xx)
PL (1) PL192651B1 (xx)
PT (1) PT1035835E (xx)
RS (1) RS49838B (xx)
SK (1) SK284522B6 (xx)
TW (1) TW550088B (xx)
WO (1) WO1999027906A1 (xx)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6538031B1 (en) * 1999-11-25 2003-03-25 Novartis Animal Health Us, Inc. Method of controlling sea lice infestation in fish
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
US20020035107A1 (en) 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
DE10161077A1 (de) 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion
CA2472578A1 (en) * 2002-01-24 2003-07-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anti-cancer combination and use thereof
CN1275589C (zh) * 2002-05-31 2006-09-20 王玉万 含抗寄生虫药物的缓释注射剂
UY27412A1 (es) * 2002-08-12 2003-06-30 Carlson Internat Inc Un nuevo producto para el combate de garrapatas y el proceso para la prepaacinn.
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
AU2003234895A1 (en) * 2002-11-18 2004-06-15 Yuwan Wang Veterinary antiparasite suspension injection
WO2004047803A1 (fr) * 2002-11-27 2004-06-10 Eco Animal Health Ltd Injection de medicament pour animaux renfermant du closantel ou du sodium de closantel
JO2505B1 (en) * 2003-03-14 2009-10-05 باير شيرنغ فارما اكتنجيسيلشافت Pharmacy methods and formulations for obtaining acceptable serum testosterone levels
MY146351A (en) * 2003-05-29 2012-08-15 Schering Plough Ltd Compositions for treating infection in cattle and swine
CN1293921C (zh) * 2003-08-18 2007-01-10 王玉万 含乙基纤维素和脂肪酸酯类的长效注射剂
EP1568369A1 (en) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
WO2005084688A1 (fr) * 2004-03-04 2005-09-15 Yuwan Wang Poudre injectable contenant un vermifuge
NZ534939A (en) * 2004-08-26 2007-04-27 Bomac Research Ltd Injectable formulation comprising an anthelmintic compound with complexing compound for improved solubility
DE102006043444A1 (de) * 2006-09-15 2008-03-27 Bayer Cropscience Ag Suspensionskonzentrate auf Ölbasis
NZ552040A (en) * 2006-12-13 2009-04-30 Bomac Research Ltd Veterinary formulation comprising an anthelmintic compound and glyceryl acetate
GB0804619D0 (en) * 2008-03-12 2008-04-16 Norbrook Lab Ltd A topical ectoparasiticide composition
BRPI0922043B1 (pt) * 2008-11-19 2019-04-24 Merial, Inc. Composições compreendendo um aril pirazol e/ou formamidina, métodos e usos das mesmas
IN2012DN03157A (xx) 2009-10-12 2015-09-18 Boehringer Ingelheim Vetmed
AU2010347598B2 (en) 2010-03-03 2014-11-27 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
WO2014016252A1 (en) * 2012-07-27 2014-01-30 Novartis Ag New treatment of fish with a nanosus pens ion of lufenuron or hexaflumuron
BR112015013491B1 (pt) * 2012-12-12 2021-03-30 Zoetis Services Llc Composição veterinária ectoparasítica injetável e uso da mesma
FR3000392B1 (fr) 2012-12-27 2015-03-27 Virbac Nouvelles compositions pharmaceutiques veterinaires et leur procede de preparation
CN104337761B (zh) * 2013-08-07 2019-03-26 江苏豪森药业集团有限公司 氟维司群药物组合物
KR101817028B1 (ko) * 2013-12-16 2018-01-09 조에티스 서비시즈 엘엘씨 지속성 케토프로펜 조성물
CN103721266A (zh) * 2014-01-06 2014-04-16 王玉万 含阿维菌素类药物/氢化蓖麻油的原位胶凝注射剂
AU2016274949B2 (en) * 2015-06-10 2021-07-15 Dechra Veterinary Products, Llc Injectable antibiotic formulations and use thereof
WO2020223959A1 (en) * 2019-05-09 2020-11-12 The Procter & Gamble Company Stable anti-mite liquid laundry detergent composition comprising benzyl benzoate
CN110585124A (zh) * 2019-09-26 2019-12-20 西安力邦医药科技有限责任公司 一种含有雌三醇或其衍生物的油性注射剂

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1060632A (en) * 1962-09-11 1967-03-08 Olin Mathieson Steroid compositions
DE2548413A1 (de) * 1975-10-27 1977-04-28 Schering Ag Depotpraeparate in oeliger ungesaettigter loesung zur intramuskulaeren injektion
US4330538A (en) * 1977-12-23 1982-05-18 Schering Aktiengesellschaft Use of estradiol valerate as an anti-depressant
EP0413538A1 (en) * 1989-08-14 1991-02-20 Merck & Co. Inc. Long active injectable formulations containing triacetin
EP0535734A1 (en) * 1991-09-30 1993-04-07 Merck & Co. Inc. Long acting injectable formulations containing hydrogenated castor oil
WO1997011709A1 (en) * 1995-09-25 1997-04-03 Ashmont Holdings Limited Anthelmintic macrocyclic lactone compositions
DE19613972A1 (de) * 1996-04-09 1997-10-16 Bayer Ag Injektionsformulierungen von Avermectinen und Milbemycinen auf Basis von Rizinusöl

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE434277B (sv) * 1976-04-19 1984-07-16 Merck & Co Inc Sett att framstella nya antihelmintiskt verkande foreningar genom odling av streptomyces avermitilis
US4199569A (en) * 1977-10-03 1980-04-22 Merck & Co., Inc. Selective hydrogenation products of C-076 compounds and derivatives thereof
US4427663A (en) * 1982-03-16 1984-01-24 Merck & Co., Inc. 4"-Keto-and 4"-amino-4"-deoxy avermectin compounds and substituted amino derivatives thereof
EP0237482A1 (de) * 1986-03-06 1987-09-16 Ciba-Geigy Ag C(29)-Carbonyloxi-milbemycin-Derivate zur Bekämpfung von tier- und pflanzenparasitären Schädlingen
RU2024527C1 (ru) * 1986-03-25 1994-12-15 Санкио Компани Лимитед Способ получения макролидных соединений
EP0252879B1 (de) * 1986-07-02 1992-05-06 Ciba-Geigy Ag Pestizide
US4855317A (en) * 1987-03-06 1989-08-08 Ciba-Geigy Corporation Insecticides and parasiticides
US4871719A (en) * 1987-03-24 1989-10-03 Ciba-Geigy Corporation Composition for controlling parasites in productive livestock
US4874749A (en) * 1987-07-31 1989-10-17 Merck & Co., Inc. 4"-Deoxy-4-N-methylamino avermectin Bla/Blb
EP0319142B1 (en) * 1987-11-03 1994-04-06 Beecham Group Plc Intermediates for the preparation of anthelmintic macrolide antibiotics
NZ232422A (en) * 1989-02-16 1992-11-25 Merck & Co Inc 13-ketal milbemycin derivatives and parasiticides

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1060632A (en) * 1962-09-11 1967-03-08 Olin Mathieson Steroid compositions
DE2548413A1 (de) * 1975-10-27 1977-04-28 Schering Ag Depotpraeparate in oeliger ungesaettigter loesung zur intramuskulaeren injektion
US4330538A (en) * 1977-12-23 1982-05-18 Schering Aktiengesellschaft Use of estradiol valerate as an anti-depressant
EP0413538A1 (en) * 1989-08-14 1991-02-20 Merck & Co. Inc. Long active injectable formulations containing triacetin
EP0535734A1 (en) * 1991-09-30 1993-04-07 Merck & Co. Inc. Long acting injectable formulations containing hydrogenated castor oil
WO1997011709A1 (en) * 1995-09-25 1997-04-03 Ashmont Holdings Limited Anthelmintic macrocyclic lactone compositions
DE19613972A1 (de) * 1996-04-09 1997-10-16 Bayer Ag Injektionsformulierungen von Avermectinen und Milbemycinen auf Basis von Rizinusöl

Also Published As

Publication number Publication date
EA002497B1 (ru) 2002-06-27
YU34500A (sh) 2002-11-15
CN1205921C (zh) 2005-06-15
ME00855B (me) 2008-08-07
KR20010032760A (ko) 2001-04-25
CO4970836A1 (es) 2000-11-07
NZ504783A (en) 2002-12-20
TW550088B (en) 2003-09-01
SK8292000A3 (en) 2000-11-07
AR017779A1 (es) 2001-10-24
DE69818093D1 (de) 2003-10-16
JP2001524510A (ja) 2001-12-04
WO1999027906A1 (en) 1999-06-10
RS49838B (sr) 2008-08-07
AU9385898A (en) 1999-06-16
HRP20000366A2 (en) 2001-06-30
DE69818093T2 (de) 2004-06-09
EP1035835A1 (en) 2000-09-20
ES2205550T3 (es) 2004-05-01
HUP0100606A2 (hu) 2001-06-28
PL341542A1 (en) 2001-04-23
KR100499438B1 (ko) 2005-07-07
ATE249206T1 (de) 2003-09-15
BG104560A (en) 2001-04-30
IL136313A (en) 2005-08-31
CA2312898C (en) 2004-05-11
HU228617B1 (en) 2013-04-29
NO329469B1 (no) 2010-10-25
AU749006B2 (en) 2002-06-13
BG65147B1 (bg) 2007-04-30
SK284522B6 (sk) 2005-05-05
NO20002830D0 (no) 2000-06-02
IL136313A0 (en) 2001-05-20
EA200000604A1 (ru) 2000-12-25
HK1032917A1 (en) 2001-08-10
JP3925900B2 (ja) 2007-06-06
EP1035835B1 (en) 2003-09-10
CA2312898A1 (en) 1999-06-10
PL192651B1 (pl) 2006-11-30
PT1035835E (pt) 2003-12-31
NO20002830L (no) 2000-08-03
DK1035835T3 (da) 2003-12-08
BR9815352A (pt) 2000-10-17
HUP0100606A3 (en) 2002-11-28
CN1283990A (zh) 2001-02-14

Similar Documents

Publication Publication Date Title
HRP20000366B1 (en) Long acting injectable formulations containing hydrogenated castor oil
CA2259297A1 (en) Parenteral paclitaxel in a stable non-toxic formulation
DK0725648T3 (da) Leverspecifikke farmaceutiske aktivstoffer
OA09807A (fr) "Dérivé de la 5H-pyrrolo[ 3,4-b]pyrazine optiquement actif. Sa préparation et les compositions pharmaceutiques qui le contiennent".
NO971192D0 (no) Fremgangsmåter for avlevering av materialer inn i huden, og sammensetninger som blir anvendt
DE69715049T2 (de) Tranilast enthaltendes externum und verfahren zu dessen herstellung
AR002944A1 (es) Uso de una composicion de gel acuosa que contiene una o mas drogas que son eficaces para tratar hemorroides para la preparacion de un medicamento y dicha composicion de gel acuosa
MX9304710A (es) Composicion farmaceutica y/o cosmetica y su uso.
ES2171933T3 (es) Derivados de androsteno.
MXPA97007996A (es) Preparado para el transporte de sustancias activas a traves de barreras.
DE69717293T2 (de) Pharmazeutische formulierungen aus corticotropin freisetzenden faktor mit verbesserter stabilitaet in fluessiger form
WO2003018064A3 (en) Lipophilic drug compositions
KR970706253A (ko) 인돌-2-카복실산 에스테르 유도체 및 활성 성분으로서 이를 함유하는 농업용 및 원예용 살균제(indole-2-carboxylic ester derivatives and agricultural and horticultural bacteriocides containing the same as the active ingredient)
HUP9802897A3 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
ATE227973T1 (de) Kosmetische, dermatologische und pharmazeutische anwendung eines terminalia catappa pflanzenextrakts
DE69531736D1 (de) Oxytetracyclin enthaltendes arzneimittel mit verzögerter wirksoffabgabe
IT1240683B (it) Composizione farmaceutica contenente egf
CO4761022A1 (es) Pesticidas que contienen alcaloides de benzofenantridina
NO941097D0 (no) Hudregenererende kosmetisk preparat
DE69706241T2 (de) Pharmazeutische Zusammensetzung zur Behandlung der Leukämie enthaltend 9-cis-Retinoinsäure-alpha-Tocopherolester
DE59205998D1 (de) Arzneimittel mit antineoplastischer Wirkung enthaltend als Wirkstoff Octadecyl-[2-(N-methylpiperidino)-ethyl]-phosphat und Verfahren zu dessen Herstellung
AR016200A1 (es) El uso de una composicion que comprende uno o mas compuestos que contienen azufre para la fabricacion de un medicamento para aumentar la permeabilidad deltejido corneo humano, y un kit que incluye dicha composicion
HUP9802896A3 (en) Optically active piperidinoalkyl-4h-1,2,4-oxadiazine derivative, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
IT1254938B (it) Derivati otticamente attivi della n-imminoalchil-n'-((2-idrossi- 2-fenil-2-cicloesil)-etil)-piperazina
AR023938A1 (es) Composiciones estables de aminobutironitrilo quiral.

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
PNAN Change of the applicant name, address/residence

Owner name: MERCK SHARP & DOHME CORP., US

PNAN Change of the applicant name, address/residence

Owner name: MERCK SHARP & DOHME CORP., US

Owner name: SCHERING CORPORATION, US

ODRP Renewal fee for the maintenance of a patent

Payment date: 20170905

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20180914